Jaya Natarajan

Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus

Sue Sha, David Polidori, Tim Heise et al. · Diabetes Obesity and Metabolism · 2014 · 235 citations

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

Shuchean Chien, Mark Rogge, L. G. Gisclon et al. · Antimicrobial Agents and Chemotherapy · 1997 · 215 citations · Full text

Oral Levofloxacin, Therapeutic Drug Monitoring, Pharmacokinetic Profile +10

Levofloxacin Population Pharmacokinetics and Creation of a Demographic Model for Prediction of Individual Drug Clearance in Patients with Serious Community-Acquired Infection

Sandra L. Preston, George L. Drusano, Adam L. Berman et al. · Antimicrobial Agents and Chemotherapy · 1998 · 116 citations · Full text

Pharmacokinetics of a contraceptive patch (Evra^™/Ortho Evra^™) containing norelgestromin and ethinyloestradiol at four application sites

Larry S. Abrams, Donna Skee, Jaya Natarajan et al. · British Journal of Clinical Pharmacology · 2002 · 91 citations · Full text

Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study

Sue Sha, David Polidori, Kristin Farrell et al. · Diabetes Obesity and Metabolism · 2014 · 90 citations · Full text